Observational studyFrontiers in public health2025
Burden, trends and projections of liver cancer in China and G20 countries: a comparative study based on the global burden of disease database 2021.
Observational study in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Time trends in the burden of scabies from 1990 to 2021, and projections to 2050: Insights based on the Global Burden of Disease Study 2021.PLoS neglected tropical diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to comprehensively compare and analyze the burden of liver cancer in China and the Group of 20 (G20) countries from 1990 to 2021, based on the latest Global Burden of Disease (GBD) 2021 database. It also predicts the trends in liver cancer incidence, prevalence, mortality, and disability-adjusted life years (DALYs) in China and G20 countries over the next 15 years. Methods: This observational longitudinal study utilizes data from the GBD 2021 database, employing indicators that include incidence, mortality, prevalence, DALYs, and age-standardized rates (ASRs) to assess liver cancer trends. The Joinpoint regression model was used to calculate the annual average percentage change (AAPC) to determine long-term trends of significant changes in liver cancer occurrence in China and G20 countries. The autoregressive integrated moving average (ARIMA) model was employed to predict the burden trends of liver cancer in China and G20 countries from 2022 to 2036. Results: In 2021, the age-standardized incidence rate (ASIR), the age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR) (95% CI) for liver cancer in China were 9.52 (7.72-11.78), 13.29 (10.75-16.41), 8.35 (6.80-10.29) and 239.91 (191.98-299.37) per 100,000 people respectively, indicating a decrease compared to 1990. The ASIR, ASPR, ASMR, and ASDR for G20 countries in 1990 and 2021 were substantially lower than those of China during the same periods. Joinpoint regression analysis demonstrated an overall decline in the ASMR and ASDR of liver cancer in China and G20 countries from 1990 to 2021. Liver cancer incidents and deaths caused by five etiologies also increased from 1990 to 2021, and non-alcoholic steatohepatitis (NASH) was the largest increasing etiologies in China. Infections with hepatitis B virus (HBV) remained the leading etiology of liver cancer in China and G20 countries. Projections indicate that between 2022 and 2036, both China and G20 countries will experience predominantly modest changes in ASRs. Conclusion: Due to the implementation of preventive strategies, advancements in healthcare, and improved economic conditions, the incidence, prevalence, mortality, and DALYs of liver cancer in China have decreased. However, there remains a certain gap compared to G20 countries at the same time. In the future, China should develop more detailed prevention and control strategies targeting risk factors, tailored to men, women, and different age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.